COVID-19 Pandemic
Conditions
Keywords
COVID-19 Intensive Care Unit, Famotidine, mortality, entubation
Brief summary
The COVID-19 disease, caused by SARS-CoV-2 virus, started in December 2019 and created a pandemic with high mortality and morbidity. Since a fully proven treatment has not been developed, the efficacy of currently available treatments is being investigated. Famotidine, an H2Receptor blocker, is one of the drug treatments being investigated. In this study, we aimed to investigate the effect of Famotidine treatment on the clinic and mortality of Covid-19 patients treated in the intensive care unit.
Detailed description
The computer and written records of the patients followed in the Covid-19 Intensive Care Units of a research hospital during the pandemic process will be examined. Patients over the age of 18 who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR (Polymeraze Chaine Reaction) will be included in the study. Patients with immunosuppression, end-stage renal disease, liver disease, G6PD deficiency, ALT/AST \>5, long QT syndrome in ECG, diagnosed with psoriasis, porphyria, pregnant, and allergic reactions to famotidine or similar drugs were excluded from the study. Patients' age, gender, comorbidities, smoking and APACHE II score will be recorded. Patients who were administered Famotidine 160 mg/day PO or nasogastric and were not given this treatment since their admission to the intensive care unit will be compared. The primary outcome will be the need for invasive mechanical ventilation, intensive care mortality, and both. As a secondary outcome, serum markers indicating the severity of the disease (Leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, CRP, D-Dimer, fibrinogen, procalcitonin, IL-6, troponin, creatinine, AST, ALT, P/F ratio and lactate) will be recorded.
Interventions
DRUGFamotidine Tablets
160 mg/day Famotidine
Sponsors
Istanbul Medeniyet University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR
Exclusion criteria
* immunosuppression * end-stage renal disease * liver disease * G6PD deficiency * long QT syndrome in ECG * psoriasis * porphyria * pregnant * allergic reactions to famotidine or similar drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who died in intensive care | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | Mortality in intensive care |
| Number of patients who were intubated in intensive care | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | Development of respiratory distress requiring intubation in the patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| D-Dimer | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | D-Dimer in nonogram/miiliter |
| Ferritin | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | Ferritin in nonogram/miiliter |
| Procalcitonin | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | Procalcitonin in nonogram/miiliter |
| Fibrinogen | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | Fibrinogen in nonogram/miiliter |
| CRP | Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date | C-Reactive protein in miligram/liter |
Countries
Turkey (Türkiye)
Outcome results
None listed